Florian Fitzal

Florian Fitzal

Heinrich Collin Str. 30
Vienna, 1140, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 127 publications

The Xpert Breast Cancer Insight Test Predicts Distant Recurrence and Overall Survival in ER-Positive, HER2-Negative Early Breast Cancer.

The Xpert Breast Cancer Insight Test Predicts Distant Recurrence and Overall Survival in ER-Positive, HER2-Negative Early Breast Cancer.

Journal: Clinical breast cancer

Published: April 01, 2026

Surgical Outcome Parameters in Breast Cancer: A Survey Comparing Oncoplastic and Non-Oncoplastic Surgeons as well as Certified with Non-Certified Breast Health Centers.

Surgical Outcome Parameters in Breast Cancer: A Survey Comparing Oncoplastic and Non-Oncoplastic Surgeons as well as Certified with Non-Certified Breast Health Centers.

Journal: Breast care (Basel, Switzerland)

Published: July 03, 2025

Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109).

Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109).

Journal: ESMO open

Published: November 14, 2024

Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trials.

Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trials.

Journal: Breast (Edinburgh, Scotland)

Published: November 14, 2024

Mass spectrometry-based analysis of eccrine sweat supports predictive, preventive and personalised medicine in a cohort of breast cancer patients in Austria.

Mass spectrometry-based analysis of eccrine sweat supports predictive, preventive and personalised medicine in a cohort of breast cancer patients in Austria.

Journal: The EPMA journal

Published: October 09, 2024

HER2 and HER3 expression during neoadjuvant treatment of HER2-negative early breast cancer: potential for biomarker-driven sequencing of T-DXd and HER3-DXd.

HER2 and HER3 expression during neoadjuvant treatment of HER2-negative early breast cancer: potential for biomarker-driven sequencing of T-DXd and HER3-DXd.

Journal: Cancer communications (London, England)

Published: August 01, 2024

Correction: Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?

Correction: Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?

Journal: Breast cancer research and treatment

Published: May 05, 2024

Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy.

Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy.

Journal: JAMA oncology

Published: April 25, 2024

Monocyte subsets in breast cancer patients under treatment with aromatase inhibitor and mucin-1 cancer vaccine.

Monocyte subsets in breast cancer patients under treatment with aromatase inhibitor and mucin-1 cancer vaccine.

Journal: Journal of translational medicine

Published: April 25, 2024

Prognostic relevance of the neurological symptom burden in brain metastases from breast cancer.

Prognostic relevance of the neurological symptom burden in brain metastases from breast cancer.

Journal: British journal of cancer

Published: March 03, 2024

Patient Satisfaction, Esthetic Outcome, and Quality of Life in Oncoplastic and Reconstructive Breast Surgery: A Single Center Experience.

Patient Satisfaction, Esthetic Outcome, and Quality of Life in Oncoplastic and Reconstructive Breast Surgery: A Single Center Experience.

Journal: Breast care (Basel, Switzerland)

Published: December 18, 2023

Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer.

Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer.

Journal: Oncoimmunology

Published: November 29, 2023

Showing 1-12 of 127

Last Updated: 09/26/2026